RxDoctor Payments Data

Ma Theresa Egasani Elises, MD

Family Medicine · Walnut Creek, CANPI 1992954465

Payments from drug & device makers

$15,612in general payments, 2019–2025

Across 756 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • Pfizer$982
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,47299%
  • Education$1401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)103$2,460
AbbVie(2 entities)89$1,677
Novo Nordisk94$1,434
Boehringer Ingelheim56$1,156
Lilly USA, LLC48$1,023
Pfizer53$982
Amarin Pharma, Inc.36$779
AstraZeneca(2 entities)26$699
Bayer18$429
Otsuka America Pharmaceutical, Inc.16$364
IBSA Pharma Inc.11$343
Sanofi-aventis U.S. LLC16$342
Mannkind Corporation14$306
GSK12$296
Radius Health, Inc.12$240
Abbott13$230
Exact Sciences10$227
Currax Pharmaceuticals LLC15$207
Merck10$191
Corcept Therapeutics10$186
Bausch Health US, LLC9$180
Astellas Pharma US Inc4$159
Biohaven Pharmaceuticals, Inc.6$156
Biohaven Pharmaceutical Holding Company Ltd.6$124
Xeris Pharmaceuticals, Inc.6$118
Ascendis Pharma Endocrinology Inc4$112
Dexcom, Inc.3$97
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$76
Endo Pharmaceuticals Inc.4$72
Johnson & Johnson3$64
Ascensia Diabetes Care US Inc.3$63
Averitas Pharma Inc.2$51
Gilead3$51
Ipsen Biopharmaceuticals, Inc2$43
Takeda Pharmaceuticals U.S.A., Inc.3$39
Agios Pharmaceuticals, Inc.1$38
Lundbeck LLC2$37
Vanda Pharmaceuticals Inc.1$31
Mayne Pharma Commercial LLC2$31
Amryt Pharma Holdings Ltd1$30
Companion Medical, Inc.2$29
Neurocrine Biosciences, Inc.1$29
Embecta Corp.1$27
Insulet Corporation2$26
Dynavax Technologies Corporation2$25
Esperion Therapeutics, Inc.1$24
AMAG Pharmaceuticals, Inc.1$23
VBI Vaccine (delaware) Inc.1$22
Sumitomo Pharma America, Inc.1$22
Antares Pharma, Inc.1$21
Lifescan, Inc.1$20
Cequr Corporation1$19
Focal Therapeutics, Inc.1$19
Mylan Pharmaceuticals Inc.1$19
Phadia US Inc.1$19
Optinose US, Inc.1$19
Tandem Diabetes Care, Inc.1$18
Acella Pharmaceuticals, LLC1$17
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$16
Teva Pharmaceuticals USA, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,612 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$156,377
Medicare patients
336
Services billed
3,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$148,547
JardianceEmpagliflozin64$94,449
EliquisApixaban32$40,454
FarxigaDapagliflozin Propanediol24$36,008
TrulicityDulaglutide15$24,177
MounjaroTirzepatide17$20,877
XareltoRivaroxaban13$19,838
VyvanseLisdexamfetamine Dimesylate13$8,608
SynthroidLevothyroxine Sodium45$3,969
Atorvastatin Calcium325$3,148
Levothyroxine Sodium212$2,792
Budesonide14$2,625
Gabapentin92$2,159
Albuterol Sulfate HfaAlbuterol Sulfate36$1,603
Quetiapine Fumarate43$1,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,434$148,547101 claims
Boehringer IngelheimJardiance$1,156$94,44964 claims
Lilly USA, LLCTrulicity, Mounjaro$1,023$45,05532 claims
PfizerEliquis$982$40,45432 claims
AstraZenecaFarxiga$699$36,00824 claims
Johnson & JohnsonXarelto$64$19,83813 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$39$8,60813 claims
AbbVieSynthroid$1,677$3,96945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →